{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-003459","form_type":"8-K","ticker":"VOR","cik":"0001817229","company_name":"Vor Biopharma Inc.","filed_at":"2024-01-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.659566+00:00","generated_at":"2026-06-07T03:18:17.287909+00:00","sec_items":["8.01","9.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"confidence":"low","headline":"Vor Biopharma updates investor presentation; no material new information disclosed","bullets":["Filed an updated corporate presentation under Item 8.01 on January 5, 2024.","Presentation reiterates ambition to cure blood cancers via cell and genome engineering.","No financial results, guidance, clinical data, or strategic updates were provided.","Exhibit 99.1 includes only a title slide; full content was not disclosed in the filing.","The update appears routine with no new business developments."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-003459","json":"https://secwatch.observer/filing/0001193125-24-003459.json","markdown":"https://secwatch.observer/filing/0001193125-24-003459.md","text":"https://secwatch.observer/filing/0001193125-24-003459.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1817229/000119312524003459/0001193125-24-003459-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1817229/000119312524003459/d703283d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T03:18:17.287909+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}